| Year |
Citation |
Score |
| 2020 |
Zhang H, Qi L, Du Y, Huang LF, Braun FK, Kogiso M, Zhao Y, Li C, Lindsay H, Zhao S, Injac SG, Baxter PA, Su JM, Stephan C, Keller C, et al. Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma. Cancers. 12. PMID 32517016 DOI: 10.3390/Cancers12061478 |
0.34 |
|
| 2020 |
Harrold AP, Cleary MM, Bharathy N, Lathara M, Berlow NE, Foreman NK, Donson AM, Amani V, Zuercher WJ, Keller C. In vitro benchmarking of NF-κB inhibitors. European Journal of Pharmacology. 172981. PMID 32014486 DOI: 10.1016/J.Ejphar.2020.172981 |
0.668 |
|
| 2019 |
Kats D, Ricker CA, Berlow NE, Noblet B, Nicolle D, Mevel K, Branchereau S, Judde JG, Stiverson CD, Stiverson CL, Svalina MN, Settelmeyer T, Matlock K, Lathara M, Mussini C, ... ... Keller C, et al. Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget. 10: 6403-6417. PMID 31741706 DOI: 10.18632/Oncotarget.27237 |
0.354 |
|
| 2019 |
Yohe ME, Heske CM, Stewart E, Adamson PC, Ahmed N, Antonescu CR, Chen E, Collins N, Ehrlich A, Galindo RL, Gryder BE, Hahn H, Hammond S, Hatley ME, Hawkins DS, ... ... Keller C, et al. Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood & Cancer. e27869. PMID 31222885 DOI: 10.1002/Pbc.27869 |
0.326 |
|
| 2019 |
Berlow NE, Rikhi R, Geltzeiler M, Abraham J, Svalina MN, Davis LE, Wise E, Mancini M, Noujaim J, Mansoor A, Quist MJ, Matlock KL, Goros MW, Hernandez BS, Doung YC, ... ... Keller C, et al. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. Bmc Cancer. 19: 593. PMID 31208434 DOI: 10.1186/S12885-019-5681-6 |
0.316 |
|
| 2019 |
Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Bajwa Z, Goros MW, Hernandez BS, Wolff JE, Pal R, Davies AM, Ashok A, Bushby D, ... ... Keller C, et al. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma. Skeletal Muscle. 9: 12. PMID 31113472 DOI: 10.1186/S13395-019-0198-X |
0.389 |
|
| 2019 |
Wei Q, Ramsey SA, Larson MK, Berlow NE, Ochola D, Shiprack C, Kashyap A, Séguin B, Keller C, Löhr CV. Elucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach. Bmc Cancer. 19: 311. PMID 30947707 DOI: 10.1186/S12885-019-5501-Z |
0.315 |
|
| 2019 |
Zhang H, Qi L, Du Y, Braun F, Kogiso M, Huang L, Klisch T, Zhao Y, Guo L, Li C, Zhao S, Lindsay HB, Injac S, Baxter P, Su J, ... ... Keller C, et al. TMOD-21. TARGETING ANAPLASTIC MENINGIOMA WITH PANOBINOSTAT IN PATIENT-DERIVED ORTHOTOPIC XENOGRAFT (PDOX) MODELS DERIVED FROM A MATCHING PAIR OF PRIMARY AND RECURRENT TUMORS Neuro-Oncology. 21: vi267-vi267. DOI: 10.1093/Neuonc/Noz175.1120 |
0.385 |
|
| 2018 |
Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Ishikawa Y, Zientek K, Bajwa Z, Goros MW, Hernandez BS, Wolff JE, Rudek MA, Xu L, ... ... Keller C, et al. The HDAC3-SMARCA4-miR-27a axis promotes expression of the fusion oncogene in rhabdomyosarcoma. Science Signaling. 11. PMID 30459282 DOI: 10.1126/Scisignal.Aau7632 |
0.678 |
|
| 2018 |
Malempati S, Chang BH, Reid JM, Liu X, Minard CG, Keller C, Fox E, Weigel B. ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors. Journal of Clinical Oncology. 36: 10556-10556. DOI: 10.1200/Jco.2018.36.15_Suppl.10556 |
0.336 |
|
| 2018 |
Cairo S, Noblet B, Rasmussen S, Svalina MN, Mevel K, Ven EL, Nicolle D, Déas O, Mussini C, Branchereau S, Judde J, Keller C. Abstract 4628: Tailoring personalized strategies for children with treatment-refractory liver cancer Cancer Research. 78: 4628-4628. DOI: 10.1158/1538-7445.Am2018-4628 |
0.394 |
|
| 2017 |
Davis LE, Jeng S, Svalina MN, Huang E, Pittsenbarger J, Cantor EL, Berlow N, Seguin B, Mansoor A, McWeeney SK, Keller C. Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species. Oncotarget. 8: 76241-76256. PMID 29100308 DOI: 10.18632/Oncotarget.19532 |
0.391 |
|
| 2017 |
Bharathy N, Svalina MN, Settelmeyer TP, Cleary MM, Berlow NE, Airhart SD, Xiang S, Keck J, Hayden JB, Shern JF, Mansoor A, Lathara M, Srinivasa G, Langenau DM, Keller C. Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma. Oncotarget. 8: 62976-62983. PMID 28968964 DOI: 10.18632/Oncotarget.18520 |
0.375 |
|
| 2017 |
Cleary MM, Mansoor A, Settelmeyer T, Ijiri Y, Ladner KJ, Svalina MN, Rubin BP, Guttridge DC, Keller C. NFκB signaling in alveolar rhabdomyosarcoma. Disease Models & Mechanisms. 10: 1109-1115. PMID 28883017 DOI: 10.1242/Dmm.030882 |
0.457 |
|
| 2017 |
Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A, Kaur P, Bult CJ, Goros MW, Michalek JE, Xiang S, Keck J, Krasnoperov V, Gill P, Keller C. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. Plos One. 12: e0183161. PMID 28817624 DOI: 10.1371/Journal.Pone.0183161 |
0.377 |
|
| 2017 |
Ignatius MS, Hayes MN, Lobbardi R, Chen EY, McCarthy KM, Sreenivas P, Motala Z, Durbin AD, Molodtsov A, Reeder S, Jin A, Sindiri S, Beleyea BC, Bhere D, Alexander MS, ... ... Keller C, et al. The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Reports. 19: 2304-2318. PMID 28614716 DOI: 10.1016/J.Celrep.2017.05.061 |
0.362 |
|
| 2017 |
Matlock K, Berlow N, Keller C, Pal R. Combination therapy design for maximizing sensitivity and minimizing toxicity. Bmc Bioinformatics. 18: 116. PMID 28361667 DOI: 10.1186/S12859-017-1523-1 |
0.343 |
|
| 2016 |
Ricker CA, Pan Y, Gutmann DH, Keller C. Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. Frontiers in Oncology. 6: 259. PMID 28066715 DOI: 10.3389/Fonc.2016.00259 |
0.385 |
|
| 2016 |
Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Settelmeyer TP, Young MC, Peckham JL, Cho YJ, Michalek JE, Hernandez BS, Berlow NE, Jackson M, Guillaume DJ, Selden NR, ... ... Keller C, et al. IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma. Scientific Reports. 6: 27012. PMID 27255663 DOI: 10.1038/Srep27012 |
0.314 |
|
| 2015 |
Hooper JE, Cantor EL, Ehlen MS, Banerjee A, Malempati S, Stenzel P, Woltjer RL, Gandour-Edwards R, Goodwin NC, Yang Y, Kaur P, Bult CJ, Airhart SD, Keller C. A Patient-Derived Xenograft Model of Parameningeal Embryonal Rhabdomyosarcoma for Preclinical Studies. Sarcoma. 2015: 826124. PMID 26696773 DOI: 10.1155/2015/826124 |
0.376 |
|
| 2015 |
Zhu B, Zhang M, Williams EM, Keller C, Mansoor A, Davie JK. TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle. Oncogene. PMID 26686089 DOI: 10.1038/Onc.2015.486 |
0.428 |
|
| 2015 |
Noujaim J, Thway K, Sheri A, Keller C, Jones RL. Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors. International Journal of Surgical Pathology. PMID 26399578 DOI: 10.1177/1066896915606971 |
0.308 |
|
| 2015 |
Noujaim J, Thway K, Bajwa Z, Bajwa A, Maki RG, Jones RL, Keller C. Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. Frontiers in Oncology. 5: 186. PMID 26347853 DOI: 10.3389/Fonc.2015.00186 |
0.303 |
|
| 2015 |
Faggi F, Codenotti S, Poliani PL, Cominelli M, Chiarelli N, Colombi M, Vezzoli M, Monti E, Bono F, Tulipano G, Fiorentini C, Zanola A, Lo HP, Parton RG, Keller C, et al. MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line. Plos One. 10: e0130287. PMID 26086601 DOI: 10.1371/Journal.Pone.0130287 |
0.385 |
|
| 2015 |
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, ... ... Keller C, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine. 21: 555-9. PMID 25939062 DOI: 10.1038/Nm.3855 |
0.339 |
|
| 2015 |
Geltzeiler M, Li G, Abraham J, Keller C. The case for primary salivary rhabdomyosarcoma. Frontiers in Oncology. 5: 74. PMID 25883905 DOI: 10.3389/Fonc.2015.00074 |
0.41 |
|
| 2015 |
Faggi F, Chiarelli N, Colombi M, Mitola S, Ronca R, Madaro L, Bouche M, Poliani PL, Vezzoli M, Longhena F, Monti E, Salani B, Maggi D, Keller C, Fanzani A. Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Laboratory Investigation; a Journal of Technical Methods and Pathology. 95: 585-602. PMID 25822667 DOI: 10.1038/Labinvest.2015.45 |
0.387 |
|
| 2015 |
Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Peckham JL, Cho Y, Jackson M, Guillaume DJ, Selden NR, Bigner DD, Nazemi KJ, Green SC, Corless CL, Gultekin S, ... ... Keller C, et al. Abstract A08: IGF1R as a key target in high risk, metastatic medulloblastoma Brain. 75. DOI: 10.1158/1538-7445.Brain15-A08 |
0.393 |
|
| 2015 |
Ignatius M, Lobbardi R, Hayes M, Chen E, McCarthy K, Nielsen GP, Beleyea B, Linardic C, Khan J, Keller C, Langenau DM. Abstract 4733: Notch signaling increases the number of relapse-driving tumor propagating cells in embryonal rhabdomyosarcoma Cancer Research. 75: 4733-4733. DOI: 10.1158/1538-7445.Am2015-4733 |
0.411 |
|
| 2015 |
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily M, Quist MJ, Davis L, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung T, Sun W, Kogiso M, ... ... Keller C, et al. BT-02 * FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA Neuro-Oncology. 17: iii3-iii3. DOI: 10.1093/Neuonc/Nov061.12 |
0.36 |
|
| 2014 |
Berlow N, Haider S, Qian Wan, Geltzeiler M, Davis LE, Keller C, Pal R. An Integrated Approach to Anti-Cancer Drug Sensitivity Prediction. Ieee/Acm Transactions On Computational Biology and Bioinformatics / Ieee, Acm. 11: 995-1008. PMID 26357038 DOI: 10.1109/Tcbb.2014.2321138 |
0.33 |
|
| 2014 |
Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, ... ... Keller C, et al. Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harbor Perspectives in Medicine. 4: a025650. PMID 25368019 DOI: 10.1101/Cshperspect.A025650 |
0.38 |
|
| 2014 |
Svalina MN, Keller C. YAPping about differentiation therapy in muscle cancer. Cancer Cell. 26: 154-5. PMID 25117705 DOI: 10.1016/J.Ccr.2014.07.011 |
0.342 |
|
| 2014 |
Abraham J, Nuñez-Álvarez Y, Hettmer S, Carrió E, Chen HI, Nishijo K, Huang ET, Prajapati SI, Walker RL, Davis S, Rebeles J, Wiebush H, McCleish AT, Hampton ST, Bjornson CR, ... ... Keller C, et al. Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes & Development. 28: 1578-91. PMID 25030697 DOI: 10.1101/Gad.238733.114 |
0.612 |
|
| 2014 |
Davare MA, Lal S, Peckham JL, Prajapati SI, Gultekin SH, Rubin BP, Keller C. Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells. Biochemical and Biophysical Research Communications. 450: 555-60. PMID 24928387 DOI: 10.1016/J.Bbrc.2014.06.018 |
0.326 |
|
| 2014 |
Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: 6383-8. PMID 24733895 DOI: 10.1073/Pnas.1403608111 |
0.385 |
|
| 2014 |
Chen EY, DeRan MT, Ignatius MS, Grandinetti KB, Clagg R, McCarthy KM, Lobbardi RM, Brockmann J, Keller C, Wu X, Langenau DM. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: 5349-54. PMID 24706870 DOI: 10.1073/Pnas.1317731111 |
0.34 |
|
| 2014 |
Kikuchi K, Hettmer S, Aslam MI, Michalek JE, Laub W, Wilky BA, Loeb DM, Rubin BP, Wagers AJ, Keller C. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. Plos Genetics. 10: e1004107. PMID 24453992 DOI: 10.1371/Journal.Pgen.1004107 |
0.43 |
|
| 2014 |
Sokolowski E, Turina CB, Kikuchi K, Langenau DM, Keller C. Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. Oncogene. 33: 1877-89. PMID 23665679 DOI: 10.1038/Onc.2013.129 |
0.333 |
|
| 2013 |
Jothi M, Mal M, Keller C, Mal AK. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Molecular Cancer Therapeutics. 12: 2663-74. PMID 24107448 DOI: 10.1158/1535-7163.Mct-13-0277 |
0.434 |
|
| 2013 |
He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas-Ahner J, Wang J, Bloomston M, Muscarella P, Nau P, Shah N, Butchbach ME, Ladner K, Adamo S, Rudnicki MA, ... Keller C, et al. NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. The Journal of Clinical Investigation. 123: 4821-35. PMID 24084740 DOI: 10.1172/Jci68523 |
0.362 |
|
| 2013 |
Chen EY, Dobrinski KP, Brown KH, Clagg R, Edelman E, Ignatius MS, Chen JY, Brockmann J, Nielsen GP, Ramaswamy S, Keller C, Lee C, Langenau DM. Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma. Plos Genetics. 9: e1003727. PMID 24009521 DOI: 10.1371/Journal.Pgen.1003727 |
0.36 |
|
| 2013 |
Aslam MI, Hettmer S, Abraham J, Latocha D, Soundararajan A, Huang ET, Goros MW, Michalek JE, Wang S, Mansoor A, Druker BJ, Wagers AJ, Tyner JW, Keller C. Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma. Molecular Cancer Research : McR. 11: 1303-13. PMID 23928059 DOI: 10.1158/1541-7786.Mcr-12-0598 |
0.307 |
|
| 2013 |
Balkhi MY, Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Science Signaling. 6: ra63. PMID 23901138 DOI: 10.1126/Scisignal.2004177 |
0.337 |
|
| 2013 |
Li G, Kikuchi K, Radka M, Abraham J, Rubin BP, Keller C. IL-4 receptor blockade abrogates satellite cell: rhabdomyosarcoma fusion and prevents tumor establishment. Stem Cells (Dayton, Ohio). 31: 2304-12. PMID 23897781 DOI: 10.1002/Stem.1491 |
0.399 |
|
| 2013 |
Berlow N, Davis LE, Cantor EL, Séguin B, Keller C, Pal R. A new approach for prediction of tumor sensitivity to targeted drugs based on functional data. Bmc Bioinformatics. 14: 239. PMID 23890326 DOI: 10.1186/1471-2105-14-239 |
0.326 |
|
| 2013 |
Keller C, Guttridge DC. Mechanisms of impaired differentiation in rhabdomyosarcoma. The Febs Journal. 280: 4323-34. PMID 23822136 DOI: 10.1111/Febs.12421 |
0.408 |
|
| 2013 |
Kikuchi K, Wettach GR, Ryan CW, Hung A, Hooper JE, Beadling C, Warrick A, Corless CL, Olson SB, Keller C, Mansoor A. MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma. Sarcoma. 2013: 520858. PMID 23766666 DOI: 10.1155/2013/520858 |
0.337 |
|
| 2013 |
Biressi S, Bjornson CR, Carlig PM, Nishijo K, Keller C, Rando TA. Myf5 expression during fetal myogenesis defines the developmental progenitors of adult satellite cells. Developmental Biology. 379: 195-207. PMID 23639729 DOI: 10.1016/J.Ydbio.2013.04.021 |
0.332 |
|
| 2013 |
Lin S, Shen H, Jin B, Gu Y, Chen Z, Cao C, Hu C, Keller C, Pear WS, Wu L. Brief report: Blockade of Notch signaling in muscle stem cells causes muscular dystrophic phenotype and impaired muscle regeneration. Stem Cells (Dayton, Ohio). 31: 823-8. PMID 23307608 DOI: 10.1002/Stem.1319 |
0.324 |
|
| 2013 |
Alabran JL, Hooper JE, Hill M, Smith SE, Spady KK, Davis LE, Peterson LS, Malempati S, Ryan CW, Acosta R, Spunt SL, Keller C. Overcoming autopsy barriers in pediatric cancer research. Pediatric Blood & Cancer. 60: 204-9. PMID 23015377 DOI: 10.1002/Pbc.24320 |
0.324 |
|
| 2013 |
Kikuchi K, Soundararajan A, Zarzabal LA, Weems CR, Nelon LD, Hampton ST, Michalek JE, Rubin BP, Fields AP, Keller C. Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 32: 286-95. PMID 22349825 DOI: 10.1038/Onc.2012.46 |
0.441 |
|
| 2013 |
Geltzeiler MN, Andersen PE, Gross ND, Cantor EL, Berlow N, Pal R, Keller C. Personalized Cancer Care for Head and Neck Squamous Cell Carcinoma Otolaryngology–Head and Neck Surgery. 149: P184-P184. DOI: 10.1177/0194599813496044A127 |
0.355 |
|
| 2013 |
Kikuchi K, Hettmer S, Aslam MI, Michalek JE, Laub W, Rubin BP, Wagers AJ, Keller C. Abstract 1747: The Pax3:Foxo1a translocation product is a cell cycle-specific modifier of the alveolar rhabdomyosarcoma tumor phenotype. Cancer Research. 73: 1747-1747. DOI: 10.1158/1538-7445.Am2013-1747 |
0.346 |
|
| 2013 |
Chen E, Dobrinski KP, Brown KH, Clagg R, Edelman E, Ignatius M, Brockmann J, Nielsen GP, Ramaswamy S, Keller C, Lee C, Langenau DM. Abstract 1412: Cross-species array comparative genomic hybridization identifies novel driver genes in embryonal rhabdomyosarcoma. Cancer Research. 73: 1412-1412. DOI: 10.1158/1538-7445.Am2013-1412 |
0.367 |
|
| 2013 |
Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC. Erratum: miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR (Science Signaling (2013) 6 (er6)) Science Signaling. 6. DOI: 10.1126/Scisignal.292Er6 |
0.328 |
|
| 2012 |
Kikuchi K, Keller C. The not-so-skinny on muscle cancer. Cancer Cell. 22: 421-2. PMID 23079652 DOI: 10.1016/J.Ccr.2012.09.018 |
0.323 |
|
| 2012 |
Marchildon F, Lala N, Li G, St-Louis C, Lamothe D, Keller C, Wiper-Bergeron N. CCAAT/enhancer binding protein beta is expressed in satellite cells and controls myogenesis. Stem Cells (Dayton, Ohio). 30: 2619-30. PMID 23034923 DOI: 10.1002/Stem.1248 |
0.35 |
|
| 2012 |
Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 426: 363-8. PMID 22960170 DOI: 10.1016/J.Bbrc.2012.08.092 |
0.405 |
|
| 2012 |
Wen Y, Bi P, Liu W, Asakura A, Keller C, Kuang S. Constitutive Notch activation upregulates Pax7 and promotes the self-renewal of skeletal muscle satellite cells. Molecular and Cellular Biology. 32: 2300-11. PMID 22493066 DOI: 10.1128/Mcb.06753-11 |
0.374 |
|
| 2012 |
Jothi M, Nishijo K, Keller C, Mal AK. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. Cell Cycle (Georgetown, Tex.). 11: 895-908. PMID 22333587 DOI: 10.4161/Cc.11.5.19346 |
0.369 |
|
| 2012 |
Ohshima-Hosoyama S, Davare MA, Prajapati SI, Abraham J, Lal S, Nelon LD, Kilcoyne A, Giles FJ, Hanes MA, Rubin BP, Keller C. Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model. Journal of Pediatric Hematology/Oncology. 34: 116-21. PMID 22146535 DOI: 10.1097/Mph.0B013E3182309Fe4 |
0.392 |
|
| 2012 |
Spunt SL, Vargas SO, Coffin CM, Skapek SX, Parham DM, Darling J, Hawkins DS, Keller C. The clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer. 118: 3002-9. PMID 22006470 DOI: 10.1002/Cncr.26620 |
0.356 |
|
| 2012 |
Londhe P, Zhu B, Abraham J, Keller C, Davie J. CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells. International Journal of Cancer. Journal International Du Cancer. 131: E437-48. PMID 21989738 DOI: 10.1002/Ijc.26478 |
0.344 |
|
| 2011 |
Amini-Nik S, Glancy D, Boimer C, Whetstone H, Keller C, Alman BA. Pax7 expressing cells contribute to dermal wound repair, regulating scar size through a β-catenin mediated process. Stem Cells (Dayton, Ohio). 29: 1371-9. PMID 21739529 DOI: 10.1002/Stem.688 |
0.301 |
|
| 2011 |
Ohshima-Hosoyama S, Davare MA, Hosoyama T, Nelon LD, Keller C. Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma. Journal of Neuro-Oncology. 105: 475-83. PMID 21633906 DOI: 10.1007/S11060-011-0619-0 |
0.339 |
|
| 2011 |
Kikuchi K, Rubin BP, Keller C. Developmental origins of fusion-negative rhabdomyosarcomas. Current Topics in Developmental Biology. 96: 33-56. PMID 21621066 DOI: 10.1016/B978-0-12-385940-2.00002-4 |
0.369 |
|
| 2011 |
Abraham J, Nelon LD, Kubicek CB, Kilcoyne A, Hampton ST, Zarzabal LA, Giles FJ, Michalek JE, Rubin BP, Keller C. Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model. Sarcoma. 2011: 130484. PMID 21559212 DOI: 10.1155/2011/130484 |
0.366 |
|
| 2011 |
Hosoyama T, Aslam MI, Abraham J, Prajapati SI, Nishijo K, Michalek JE, Zarzabal LA, Nelon LD, Guttridge DC, Rubin BP, Keller C. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2757-66. PMID 21536546 DOI: 10.1158/1078-0432.Ccr-10-3445 |
0.31 |
|
| 2011 |
Hosoyama T, Nishijo K, Prajapati SI, Li G, Keller C. Rb1 gene inactivation expands satellite cell and postnatal myoblast pools. The Journal of Biological Chemistry. 286: 19556-64. PMID 21478154 DOI: 10.1074/Jbc.M111.229542 |
0.345 |
|
| 2011 |
Abraham J, Prajapati SI, Nishijo K, Schaffer BS, Taniguchi E, Kilcoyne A, McCleish AT, Nelon LD, Giles FG, Efstratiadis A, LeGallo RD, Nowak BM, Rubin BP, Malempati S, Keller C. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Molecular Cancer Therapeutics. 10: 697-707. PMID 21447712 DOI: 10.1158/1535-7163.Mct-10-0695 |
0.382 |
|
| 2011 |
Watanabe S, Hirai H, Asakura Y, Tastad C, Verma M, Keller C, Dutton JR, Asakura A. MyoD gene suppression by Oct4 is required for reprogramming in myoblasts to produce induced pluripotent stem cells. Stem Cells (Dayton, Ohio). 29: 505-16. PMID 21425413 DOI: 10.1002/Stem.598 |
0.362 |
|
| 2011 |
Rubin BP, Nishijo K, Chen HI, Yi X, Schuetze DP, Pal R, Prajapati SI, Abraham J, Arenkiel BR, Chen QR, Davis S, McCleish AT, Capecchi MR, Michalek JE, Zarzabal LA, ... ... Keller C, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 19: 177-91. PMID 21316601 DOI: 10.1016/J.Ccr.2010.12.023 |
0.562 |
|
| 2011 |
Kikuchi K, Soundararajan A, Zarzabal LA, Weems CR, Nelson LD, Hampton ST, Michalek JA, Rubin BP, Fields AP, Keller C. Abstract 1043: Role of protein kinase Cι in alveolar rhabdomyosarcoma Cancer Research. 71: 1043-1043. DOI: 10.1158/1538-7445.Am2011-1043 |
0.422 |
|
| 2010 |
Hosoyama T, Nishijo K, Garcia MM, Schaffer BS, Ohshima-Hosoyama S, Prajapati SI, Davis MD, Grant WF, Scheithauer BW, Marks DL, Rubin BP, Keller C. A Postnatal Pax7 Progenitor Gives Rise to Pituitary Adenomas. Genes & Cancer. 1: 388-402. PMID 20811506 DOI: 10.1177/1947601910370979 |
0.336 |
|
| 2010 |
Ohshima-Hosoyama S, Hosoyama T, Nelon LD, Keller C. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. Biochemical and Biophysical Research Communications. 399: 727-32. PMID 20692232 DOI: 10.1016/J.Bbrc.2010.08.009 |
0.379 |
|
| 2010 |
Schaffer BS, Grayson MH, Wortham JM, Kubicek CB, McCleish AT, Prajapati SI, Nelon LD, Brady MM, Jung I, Hosoyama T, Sarro LM, Hanes MA, Rubin BP, Michalek JE, Clifford CB, ... ... Keller C, et al. Immune competency of a hairless mouse strain for improved preclinical studies in genetically engineered mice. Molecular Cancer Therapeutics. 9: 2354-64. PMID 20663932 DOI: 10.1158/1535-7163.Mct-10-0207 |
0.326 |
|
| 2010 |
Prajapati SI, Martinez CO, Abraham J, McCleish AT, Michalek JE, McManus LM, Rubin BP, Shireman PK, Keller C. Crimson carrier, a long-acting contrast agent for in vivo near-infrared imaging of injured and diseased muscle. Muscle & Nerve. 42: 245-51. PMID 20544935 DOI: 10.1002/Mus.21682 |
0.305 |
|
| 2010 |
Shea KL, Xiang W, LaPorta VS, Licht JD, Keller C, Basson MA, Brack AS. Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration. Cell Stem Cell. 6: 117-29. PMID 20144785 DOI: 10.1016/J.Stem.2009.12.015 |
0.327 |
|
| 2010 |
Samano AK, Ohshima-Hosoyama S, Whitney TG, Prajapati SI, Kilcoyne A, Taniguchi E, Morgan WW, Nelon LD, Lin AL, Togao O, Jung I, Rubin BP, Nowak BM, Duong TQ, Keller C. Functional evaluation of therapeutic response for a mouse model of medulloblastoma. Transgenic Research. 19: 829-40. PMID 20107895 DOI: 10.1007/S11248-010-9361-1 |
0.324 |
|
| 2010 |
Jothi M, Keller C, Mal AK. Abstract LB-20: Transcriptionally inactive PAX3-FKHR fails to induce ARMS cells differentiation Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-20 |
0.387 |
|
| 2009 |
Brack AS, Murphy-Seiler F, Hanifi J, Deka J, Eyckerman S, Keller C, Aguet M, Rando TA. BCL9 is an essential component of canonical Wnt signaling that mediates the differentiation of myogenic progenitors during muscle regeneration. Developmental Biology. 335: 93-105. PMID 19699733 DOI: 10.1016/J.Ydbio.2009.08.014 |
0.328 |
|
| 2009 |
McDonald PC, Dedhar S, Keller C. Integrin-linked kinase: both Jekyll and Hyde in rhabdomyosarcoma. The Journal of Clinical Investigation. 119: 1452-5. PMID 19504719 DOI: 10.1172/Jci39457 |
0.337 |
|
| 2009 |
Quach NL, Biressi S, Reichardt LF, Keller C, Rando TA. Focal adhesion kinase signaling regulates the expression of caveolin 3 and beta1 integrin, genes essential for normal myoblast fusion. Molecular Biology of the Cell. 20: 3422-35. PMID 19458188 DOI: 10.1091/Mbc.E09-02-0175 |
0.373 |
|
| 2009 |
Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, Cho MJ, Prajapati SI, Gelfond JA, Chisholm GB, Michalek JE, Aronow BJ, Barr FG, Randall RL, Ladanyi M, Qualman SJ, ... ... Keller C, et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Research. 69: 2902-11. PMID 19339268 DOI: 10.1158/0008-5472.Can-08-3723 |
0.391 |
|
| 2009 |
Nishijo K, Hosoyama T, Bjornson CR, Schaffer BS, Prajapati SI, Bahadur AN, Hansen MS, Blandford MC, McCleish AT, Rubin BP, Epstein JA, Rando TA, Capecchi MR, Keller C. Biomarker system for studying muscle, stem cells, and cancer in vivo. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 2681-90. PMID 19332644 DOI: 10.1096/Fj.08-128116 |
0.585 |
|
| 2009 |
Taniguchi E, Cho MJ, Arenkiel BR, Hansen MS, Rivera OJ, McCleish AT, Qualman SJ, Guttridge DC, Scott MP, Capecchi MR, Keller C. Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. Pediatric Blood & Cancer. 53: 136-44. PMID 19213072 DOI: 10.1002/Pbc.21968 |
0.602 |
|
| 2008 |
Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, Abboud HE, Legallo RD, Qualman SJ, Rubin BP, Keller C. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 27: 6550-60. PMID 18679424 DOI: 10.1038/Onc.2008.255 |
0.431 |
|
| 2008 |
Vasquez SX, Hansen MS, Bahadur AN, Hockin MF, Kindlmann GL, Nevell L, Wu IQ, Grunwald DJ, Weinstein DM, Jones GM, Johnson CR, Vandeberg JL, Capecchi MR, Keller C. Optimization of volumetric computed tomography for skeletal analysis of model genetic organisms. Anatomical Record (Hoboken, N.J. : 2007). 291: 475-87. PMID 18286615 DOI: 10.1002/Ar.20670 |
0.501 |
|
| 2007 |
Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science (New York, N.Y.). 317: 807-10. PMID 17690295 DOI: 10.1126/Science.1144090 |
0.302 |
|
| 2006 |
Johnson JT, Hansen MS, Wu I, Healy LJ, Johnson CR, Jones GM, Capecchi MR, Keller C. Virtual histology of transgenic mouse embryos for high-throughput phenotyping. Plos Genetics. 2: e61. PMID 16683035 DOI: 10.1371/Journal.Pgen.0020061 |
0.501 |
|
| 2005 |
Kindlmann GL, Weinstein DM, Jones GM, Johnson CR, Capecchi MR, Keller C. Practical vessel imaging by computed tomography in live transgenic mouse models for human tumors. Molecular Imaging. 4: 417-24. PMID 16285903 DOI: 10.2310/7290.2005.05166 |
0.536 |
|
| 2005 |
Keller C, Capecchi MR. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Research. 65: 7530-2. PMID 16140913 DOI: 10.1158/0008-5472.Can-05-0477 |
0.577 |
|
| 2004 |
Keller C, Hansen MS, Coffin CM, Capecchi MR. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes & Development. 18: 2608-13. PMID 15520281 DOI: 10.1101/Gad.1243904 |
0.59 |
|
| 2004 |
Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes & Development. 18: 2614-26. PMID 15489287 DOI: 10.1101/Gad.1244004 |
0.587 |
|
| Show low-probability matches. |